Wilforine attenuates inflammatory osteolysis by suppressing osteoclast fusion through JAK-STAT-stomatin immunoregulatory signaling

This study defines a novel immunometabolic mechanism wherein Wilforine inhibits osteoclast fusion and bone resorption by reprogramming cellular lipid metabolism and disrupting the "JAK-STAT - Stomatin - Lipid Raft" functional axis. It highlights lipid rafts as a viable immunomodulatory microenvironment in bone disorders and provides a strong multi-omics-supported rationale for developing Wilforine as a bone-targeted immunotherapeutic agent.